RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Karolinska Development Stock

Karolinska Development Stocks 2024

Karolinska Development Stocks

269.83 M

Ticker

KDEV.ST

ISIN

SE0002190926

WKN

A0M84G

In 2024, Karolinska Development had 269.83 M outstanding stocks, a 0% change from the 269.83 M stocks in the previous year.

The Karolinska Development Stocks history

YEARNUMBER OF STOCKS (undefined SEK)
2026e269.83
2025e269.83
2024e269.83
2023269.83
2022257.42
2021198.1
2020198.1
201983.42
201872.43
201769.22
201660.09
201553.15
201448.61
201348.35
201248.53
201143.91
201033.26
200933.33
200833.33
200733.33
200633.33

Karolinska Development shares outstanding

The number of shares was Karolinska Development in 2023 — This indicates how many shares 269.833 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Karolinska Development earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Karolinska Development's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Karolinska Development’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Karolinska Development's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Karolinska Development Aktienanalyse

What does Karolinska Development do?

Karolinska Development AB is a Swedish investment company focused on promoting innovative biotech companies and start-ups. The company was founded in 2003 by the government of the Stockholm region and Karolinska Institutet University. The business model of Karolinska Development is designed to make profitable investments in promising biotech companies. It specifically supports companies in the areas of cancer treatment, immunotherapy, cardiovascular diseases, as well as neurology and psychiatry. The company provides capital and expertise to turn promising innovations into successful products. Karolinska Development operates different divisions to fulfill this purpose, including Karolinska Development AB (parent company), Karolinska Development Life Science Venture AB (a specialized investment company), and Karolinska Development Management AB (portfolio management team). Karolinska Development has built a strong portfolio of companies developing innovative products and therapies. One example is Modus Therapeutics AB, which has developed a new therapy for the treatment of sickle cell anemia. Another example is Aprea AB, a developer of gene therapies for combating cancer using tumor cells and genetic sequencing. The company's history is marked by many successful investments and acquisitions. One example is the acquisition of BioChromix AB in 2012, which developed a new technology for rapid and precise diagnosis of infectious diseases. Karolinska Development also actively participates in supporting new start-ups and company formations to promote promising innovations. Karolinska Development AB plays an important role in the biotech industry and significantly supports research in drug development. Through its unique position as an investor and partner for innovative companies, Karolinska Development is a driving force in the field of biotechnology. The company's business field is characterized by high risk and requires strategic thinking and skillful maneuvering in the market. However, Karolinska Development has managed to build a solid foundation and establish itself as an important player in the biotech industry through targeted investments, acquisitions, and partnerships. In summary, Karolinska Development plays a vital role in the biotech industry in Sweden and worldwide. The company has produced many innovative companies and products through targeted investments and acquisitions, contributing to changing lives and combating diseases. With its unique position as an investor and partner for biotech companies, Karolinska Development is well-equipped to continue promoting new innovations and advancing drug development in the future. Karolinska Development ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Karolinska Development's Shares Outstanding

Karolinska Development's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Karolinska Development’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Karolinska Development’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Karolinska Development’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Karolinska Development stock

How many stocks are there of Karolinska Development?

The current number of stocks of Karolinska Development is 269.83 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Karolinska Development are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Karolinska Development evolved in recent years?

The number of shares of Karolinska Development has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Karolinska Development as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Karolinska Development?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Karolinska Development pay?

Over the past 12 months, Karolinska Development paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karolinska Development is expected to pay a dividend of 0 SEK.

What is the dividend yield of Karolinska Development?

The current dividend yield of Karolinska Development is .

When does Karolinska Development pay dividends?

Karolinska Development pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karolinska Development?

Karolinska Development paid dividends every year for the past 0 years.

What is the dividend of Karolinska Development?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karolinska Development located?

Karolinska Development is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karolinska Development kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karolinska Development from 11/2/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 11/2/2024.

When did Karolinska Development pay the last dividend?

The last dividend was paid out on 11/2/2024.

What was the dividend of Karolinska Development in the year 2023?

In the year 2023, Karolinska Development distributed 0 SEK as dividends.

In which currency does Karolinska Development pay out the dividend?

The dividends of Karolinska Development are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Karolinska Development

Our stock analysis for Karolinska Development Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karolinska Development Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.